

## Tyra Biosciences to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Feb. 19, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences:

### **36<sup>th</sup> Annual Oppenheimer Life Sciences Healthcare Conference**

Format: Virtual fireside chat and one-on-one investor meetings

Presentation Date/Time: Thursday, February 26, 2026 at 12:00pm ET

Location: Virtual

### **46<sup>th</sup> Annual TD Cowen Healthcare Conference**

Format: Hybrid presentation & fireside chat and one-on-one investor meetings

Presentation Date/Time: Wednesday, March 4<sup>th</sup>, 2026 at 11:50am ET

Location: Boston, MA

### **Leerink Global Healthcare Conference**

Format: One-on-one investor meetings

Date: March 8-11, 2026

Location: Miami, FL

### **2026 Jefferies Biotech on the Beach Summit**

Format: One-on-one investor meetings

Date: March 9-11, 2026

Location: Miami, FL

### **Barclays 28<sup>th</sup> Annual Global Healthcare Conference**

Format: One-on-one investor meetings

Date: March 10-12, 2026

Location: Miami, FL

A live webcast of the presentations can be accessed by visiting the "For Investors" page on the Tyra Biosciences [website](#) and will be available for replay following the event.

## **About Tyra Biosciences**

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. TYRA's lead precision medicine stemming from SNÅP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for low-grade upper tract urothelial carcinoma, intermediate risk non-muscle invasive bladder cancer and pediatric achondroplasia. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma. TYRA is based in Carlsbad, CA.

For more information about our science, pipeline and people, please visit [www.tyra.bio](http://www.tyra.bio) and engage with us on [LinkedIn](#).

## **Contact:**

Amy Conrad

[aconrad@tyra.bio](mailto:aconrad@tyra.bio)

SOURCE Tyra Biosciences